Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerMansoor R. Mirza, Ursula A. Matulonis, Bradley J. Monk et al.|New England Journal of Medicine|2016Cited by 2.5k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the CervixWilliam A. Peters, David S. Alberts, P.Y. Liu et al.|Journal of Clinical Oncology|2000Cited by 2.3k
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialKathleen N. Moore, Bradley J. Monk, Angeles Alvarez Secord et al.|The Lancet Oncology|2019Cited by 533
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 studyÉric Pujade-Lauraine, Bradley J. Monk, Keiichi Fujiwara et al.|The Lancet Oncology|2021Cited by 401
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian CancerJohn K. Chan, Bradley J. Monk|New England Journal of Medicine|2016Cited by 365